Khadijah Zai

Dr. Khadijah Zai

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
KZKhadijah Zai
Khadijah Zai
MHMasato Hirota
Masato Hirota
TYTakahiro Yamada
Takahiro Yamada
NINarumi Ishihara
Narumi Ishihara
TMTakeshi Mori
Takeshi Mori
YKYoshiki Katayama
Yoshiki Katayama

1 January 2020 in Bioscience of Microbiota, Food and Health
Verified
Journal Article
Open access
PDF file
KYKazuki Yuzuriha
Kazuki Yuzuriha
KYKyosuke Yakabe
Kyosuke Yakabe
HNHaruka Nagai
Haruka Nagai
SLShunyi Li
Shunyi Li
TZTakeshi Zendo
Takeshi Zendo
YKYoshiki Katayama
Yoshiki Katayama
The fraction of administered antibiotics that reach the cecum and colon causes dysbiosis of the gut microbiome, resulting in various diseases. Protection of the gut microbiome from antibiotics using antibiotic adsorbents in the cecum and colon is a promising method to overcome this issue. Previously, activated charcoal (AC) has been reported to protect the gut microbiome of host animals. AC is an adsorbent that is widely used to capture toxic compounds and overdosed drugs in the gastrointestinal tract. The specificity of adsorbents for antibiotics is critical to avoid the risk of unexpected side effects caused by nonspecific adsorption of biological compounds in the intestinal fluid, such as bile acids and essential micronutrients. Here, we have developed specific adsorbents for vancomycin (VCM), which is known to cause gut dysbiosis. The adsorbents were composed of polyethyleneglycol-based microparticles (MPs) in which a specific ligand for VCM, D-Ala-D-Ala-OH, was attached via dendrons of D-lysine to raise the content of the ligand in the MPs. The MPs successfully protected Staphylococcus lentus from VCM in vitro because of the adsorption of VCM in the culture media. Pre-administration of MPs to mice reduced the amount of free VCM in the feces to an undetectable level. This treatment minimized the effect of VCM on gut microbiota and provided protection against Clostridioides difficile infection after oral challenge with spores.

1 September 2020 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
PDF file
YMYunmei Mu
Yunmei Mu
JLJinting Li
Jinting Li
JKJeong-Hun Kang
Jeong-Hun Kang
HEHinako Eto
Hinako Eto
KZKhadijah Zai
Khadijah Zai
YKYoshiki Katayama
Yoshiki Katayama
The gut–liver axis may be involved in non-alcoholic steatohepatitis (NASH) progression. Pathogen-associated molecular patterns leak through the intestinal barrier to the liver via the portal vein to contribute to NASH development. Active vitamin D3 (1,25(OH)2D3) is a potential therapeutic agent to enhance the intestinal barrier. Active vitamin D3 also suppresses inflammation and fibrosis in the liver. However, the adverse effects of active vitamin D3 such as hypercalcemia limit its clinical use. We created a nano-structured lipid carrier (NLC) containing active vitamin D3 to deliver active vitamin D3 to the intestine and liver to elicit NASH treatment. We found a suppressive effect of the NLC on the lipopolysaccharide-induced increase in permeability of an epithelial layer in vitro. Using mice in which NASH was induced by a methionine and choline-deficient diet, we discovered that oral application of the NLC ameliorated the permeability increase in the intestinal barrier and attenuated steatosis, inflammation and fibrosis in liver at a safe dose of active vitamin D3 at which the free form of active vitamin D3 did not show a therapeutic effect. These data suggest that the NLC is a novel therapeutic agent for NASH.

2 January 2019 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
KZKhadijah Zai
Khadijah Zai
NINarumi Ishihara
Narumi Ishihara
HOHiroyuki Oguchi
Hiroyuki Oguchi
MHMasato Hirota
Masato Hirota
AKAkihiro Kishimura
Akihiro Kishimura
YKYoshiki Katayama
Yoshiki Katayama
Immunomodulatory function of all-trans retinoic acid (ATRA) has been gathering much attention for the therapy of autoimmune diseases. ATRA is a chemically unstable molecule which requires proper formulation for targeted delivery. Here we examined nanostructured lipid carrier (NLC) for the formulation of ATRA. NLC is a representative nanoparticle formulation especially suited for oral delivery. We established the preparation procedures of ATRA-containing NLC (NLC-RA) which minimizes the degradation of ATRA during the preparation process. NLC-RA thus obtained was taken up by macrophages and induced anti-inflammatory response via suppressing NF-κB signaling as well as via enhancing the production of anti-inflammatory cytokines. Moreover, NLC-RA enhanced differentiation of naïve T cells to regulatory T cells in the co-culture system with dendritic cells. These results suggest that NLC-RA is a promising alternative therapy for the autoimmune diseases especially intestinal bowel disease.

2 June 2017 in MedChemComm
Verified
Journal Article
Closed access
PDF file
ZHZahangir Hosain
Zahangir Hosain
KYKazuki Yuzuriha
Kazuki Yuzuriha
KZKhadijah Zai
Khadijah Zai
MTMasafumi Takeo
Masafumi Takeo
AKAkihiro Kishimura
Akihiro Kishimura
KHKhadijah
Khadijah
Bioactive particles directed the macrophage to anti-inflammatory phenotype.

10 April 2018 in Analytical Sciences
Verified
Journal Article
Closed access
PDF file
ENElnaz Nakhaei
Elnaz Nakhaei
KTKo Takehara
Ko Takehara
HSHikari Sato
Hikari Sato
KZKhadijah Zai
Khadijah Zai
AKAkihiro Kishimura
Akihiro Kishimura
YKYoshiki Katayama
Yoshiki Katayama
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies